Oral Cancer Drugs Deserve Parity
There have been some legislative efforts to bring parity to oral cancer drugs so that insurance companies treat them the same way as injectable cancer drugs.
The American Cancer Society takes a cautious approach to oral parity. Stephen Finan, senior director of policy for the American Cancer Society Cancer Action Network, said in an e-mail that the group is monitoring the issue "to better understand how health plans are handling coverage for both oral and injectable treatments -- specifically to make sure that affordability isn't challenged through increased premiums, stricter utilization management tools or exclusion of anti-cancer medications from formularies to contain costs."
Margaret Dick Tocknell is a reporter/editor with HealthLeaders Media.
- EHR Systems 'Immature, Costly,' AMA Says
- Better HCAHPS Scores Protect Revenue
- Narrow Networks Cut Costs, Not Quality, Economists Say
- CEO Exchange: Preparing for Population Health
- Interstate Medical Licensure Effort Advances
- 'Early Offer' Malpractice Programs May Spur Reform
- Anthem Blue Cross, 7 CA Health Systems Create New Challenger, Business Model
- 3 Strategies for Retaining Millennial Employees
- Advocate, NorthShore Deal Would Create 16-Hospital System
- How to Build a Health Plan from Scratch